

## **Executive Summary**

### **Global Vaccine Action Plan (GVAP) review and Immunization Agenda 2030 session**

#### **Background**

In the context of Global Vaccine Action Plan (GVAP) nearing its end and the development of the immunization agenda for the coming decade (IA 2030), the Decade of Vaccines Working Group (DOV WG) has been asked to focus this year's effort on carrying out an overall review of GVAP and pulling together the main lessons learned from GVAP in order to propose concrete recommendations for IA 2030, in particular with regard to its operationalisation aspects.

The GVAP review is an attempt to provide an honest reflection on what the last decade has meant for immunization under the GVAP/DOV umbrella and highlight key take home messages. Given the involvement of many of the SAGE DOV WG members in the mechanics of GVAP from its development over to its monitoring and evaluation mechanism, the review is not an external review. It is rather the result of a group of experts with an intimate understanding of GVAP using the best available sources of information (desk review and extensive stakeholder consultations provided by external consultants) and reflecting on what GVAP really was, what it got right, what didn't work and how things could be improved moving forward.

The IA 2030 document that will be presented to SAGE entails the new vision and strategies for vaccines and immunization for the next decade. The elements related to operationalization (implementation plans, M&E framework, governance) will be developed in 2021.

The IA 2030 aims at adopting a flexible and dynamic approach to overcome ongoing immunization challenges, but also to respond to new and emerging issues and harness solutions for impact. It has been developed through a process of "co-creation", seeking feedback from a wide range of stakeholders at the global, regional and country level, within and beyond immunization and health. The document has gone through multiple iterations, starting with the stakeholder workshop held in Geneva in March 2019 with the participation of over 200 stakeholders. A key milestone in the process was the dedicated consultations organized over the course of summer by WHO Regional Offices, to seek feedback specially from country governments. The various working groups have contributed to its technical content, as well as the development of goals. IA 2030 tries to strike a balance between a disease-specific approach and systems approach, expressing commitment to the existing eradication and elimination goals, but also proposing new goals for the next decade. Despite the parallel timelines, efforts have been made to align as closely as possible the process to develop the IA 2030, with the GVAP review process.

## **Purpose of the session and summary**

This session is a joint session covering GVAP review and lessons learned discussion as well as the presentation of the high-level IA 2030 document that is to be submitted to WHO governing bodies for endorsement.

The GVAP review part will present in a few slides some snapshots on the latest trends of the GVAP indicators and then focus mainly presenting the recommendations based on the lessons learned.

The objective is for SAGE to discuss the current draft recommendations and provide overall input and more detailed suggestions with regard to the lessons learned and recommendations.

Please note that as in past years the GVAP review document will be part of the background documentation to be referenced in the Executive Board (EB)/World Health Assembly (WHA) submission. Therefore the document will have to be finalised in the days following SAGE (at latest by 11 October) not allowing for any major rewriting.

The objective of the IA 2030 part is for SAGE to review and endorse the IA 2030 vision, strategic priorities and proposed goals. SAGE members have already been closely engaged during the iterative development process, providing technical guidance and input into the document. Another objective is for SAGE to discuss and provide guidance on how the GVAP review recommendations, especially those related to the operationalization of IA 2030, can be implemented.

## **Background documents in the yellow book**

- GVAP review and lessons learned report: this is the document that SAGE will be asked to comment, discuss, improve and endorse
- Immunization Agenda 2030 – A global strategy to leave no one behind

## **Background documents on the web**

- GVAP review and lessons learned report
- Immunization Agenda 2030 – A global strategy to leave no one behind
- Report on GVAP review and lessons learned: Methodology, analysis and results of stakeholder consultations  
*this annex provides the detailed summary of the methods used and the main results of the consultations*
- The GVAP Monitoring, Evaluation and Accountability (M&E/A) Framework: Review and lessons learned: *this annex is completing the M&E/A section of the GVAP review to provide additional elements of relevance when the IA2030 M&E/A will be developed*
- Global Vaccine Action Plan - Monitoring, evaluation & accountability - 2019 report  
*this is the annual update on the GVAP indicators, limited to a relatively short report only covering a selection of indicators.*
- Global Vaccine Action Plan - Progress towards GVAP-RVAP goals – 2019 regional reports  
*this is the annual compilation of the regional progress reports. They have been extensively discussed during the DoV face to face meeting in August.*
- National Immunization Coverage Scorecards 1999-2018: this document provides country by country WUENIC trends over the past 20 years for most of the antigens.